Fig. 2

SuperMApo treatment decreases peripheral pathogenic T cell response. Absolute numbers of CD4, Th1, Th17, Treg (a) or CD8 and Tc1 (b) in spleen and inguinal lymph nodes (iLN) 72 h after the first SuperMApo treatment (+ SuperMApo) or vehicle (EAE) (n = 5 mice per group). Data from a representative experiment out of 3 showing similar results, shown as mean ± SEM. c Percentages of activated caspase-positive cells in CD4⁺CD3⁺, CD8⁺CD3⁺ or total leukocytes in the spleen (n = 3 mice per group). Data from a representative experiment out of 2 showing similar results. d Percentages of ki67-positive cells in CD4⁺CD3⁺, CD8⁺CD3⁺, IL17⁺CD4⁺CD3⁺ (Th17), IFN-γ⁺CD4⁺CD3⁺ (Th1) and IFN-γ⁺CD8⁺CD3⁺ (Tc1) in the spleen and iLN (n = 5 mice per group). Data from a representative experiment out of 2 showing similar results shown as mean ± SEM. e SuperMApo- (+ SuperMApo; n = 5 mice) or vehicle-treated mouse (EAE; n = 4 mice) spleen or iLN cell proliferation with MOG_35-55 peptide stimulation (15 µg/mL) assessed by BrdU incorporation. Data expressed as T cell proliferation index (MOG/medium ratio), with mean ± SEM, from a representative experiment out of 3 showing similar results; p values are given. f Proliferation of T cells isolated from EAE mice (Teff) were cultured in presence of DC pulsed with MOG_35-55 peptide, Mycobacterium tuberculosis or CD3/CD28 antibodies, with different numbers of Tregs (Treg) isolated from the spleen of mice treated (+ SuperMApo) or not (EAE) with SuperMApo (the Treg:Teff cell ratio is indicated in the figure). Data pooled from 3 independent experiments, shown as mean ± SEM. g MOG-specific T cell in IL17⁺CD4⁺ (Th17), IFN-γ⁺CD4⁺ (Th1) and IFN-γ⁺CD8⁺ (Tc1) subsets from the spleen and iLN of SuperMApo- (+ SuperMApo) or vehicle-treated (EAE) mice (n = 4 mice per group). Data from a representative experiment out of 3 showing similar results, shown as mean ± SEM. Statistical significance was assessed by using unpaired two-tailed Student’s t test, with *p < 0.05, **p < 0.01, ***p < 0.001